europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders

07/03/2023
NEWS RELEASE

Brussels, 7 March 2023 - EuropaBio is pleased to announce that Disc Medicine has joined as a corporate member.

Disc Medicine is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for patients suffering from serious hematologic diseases. Disc Medicine is committed to bringing therapies that matter to patients with unmet medical needs.

By joining EuropaBio, Disc Medicine will be a valued contributor to the SME Platform and engage with the biotechnology industry across Europe. Its aim is to support the development of innovative medicinal products and processes, improve the regulatory environment, and foster communication with all stakeholders to ensure prompt patient access to treatments across the EU.

EuropaBio Director-General Dr. Claire Skentelbery commented “Disc Medicine is a success story for growing companies, especially as they develop within Europe. As we face a generational change in the legislation that shapes the flow innovation to patients, the voice of maturing biotech companies is critical to ensure that this flow can continue”.

John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine added: “We are very excited to be joining EuropaBio and look forward to collaborating with others in the industry as we work to bring potentially transformational treatments to patients with hematologic disorders.”

Template New member (1)

Disc Medicine joins EuropaBio


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
16/03/2023

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more
03/03/2023

For The Love of Science


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies